Abstract Tirzepatide, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown robust efficacy in treating diabetes and obesity, and in obese patients with heart failure with preserved ejection fraction (HFpEF), it reduced weight, lowered blood pressure, and improved outcomes
Hajji, N
*Aneja, A
QZ: Software, Validation, Conceptualization, Data curation, Formal Analysis, Visualization, Writing review and editing
Scaled to a 70kg human, thats 3503,500mg per dosefar beyond whats practical or cost-effective
This means each unit on the syringe holds less peptide, which can be a significant advantage when your research protocol calls for very small, nuanced doses